Ameliorative Effect of Chrysin on Adenine-Induced Chronic Kidney Disease in Rats

Badreldin H. Ali1*, Sirin A. Adham2, Mohammed Al Za’abi1, Mostafa I. Waly3, Javed Yasin4, Abderrahim Nemmar5, Nicole Schupp6

1 Departments of Pharmacology and Clinical Pharmacy, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman, 2 Department of Biology, College of Science, Sultan Qaboos University, Muscat, Oman, 3 Department of Food Science and Nutrition, College of Agricultural and Marine Sciences, Sultan Qaboos University, Muscat, Oman, 4 Departments of Internal Medicine, College of Medicine and Health Sciences, UAE University, Al Ain, United Arab Emirates, 5 Department of Physiology, College of Medicine and Health Sciences, UAE, Al Ain, United Arab Emirates, 6 Institute of Toxicology, University of Düsseldorf, Düsseldorf, Germany

* alibadreldin@hotmail.com

Abstract

Chrysin (5, 7- dihydroxyflavone) is a flavonoid with several pharmacological properties that include antioxidant, anti-inflammatory and antiapoptotic activities. In this work, we investigated some effects of three graded oral doses of chrysin (10, 50 and 250 mg/kg) on kidney structure and function in rats with experimental chronic renal disease (CKD) induced by adenine (0.25% w/w in feed for 35 days), which is known to involve inflammation and oxidative stress. Using several indices in plasma, urine and kidney homogenates, adenine was found to impair kidney function as it lowered creatinine clearance and increased plasma concentrations of creatinine, urea, neutrophil gelatinase-associated lipocalin and N-Acetyl-beta-D-glucosaminidase activity. Furthermore, it raised plasma concentrations of the uremic toxin indoxyl sulfate, some inflammatory cytokines and urinary albumin concentration. Renal morphology was severely damaged and histopathological markers of inflammation and fibrosis were especially increased. Most of these adenine-induced actions were moderately and dose-dependently mitigated by chrysin, especially at the highest dose. Chrysin did not cause any overt adverse effect on the treated rats. The results suggest that different doses of chrysin produce variable salutary effects against adenine-induced CKD in rats, and that, pending further pharmacological and toxicological studies, its usability as a possible ameliorative agent in human CKD should be considered.

Introduction

Chronic kidney disease (CKD) is a major and growing public health problem [1–3] and is now considered a key determinant of the poor health outcomes of major non—communicable diseases [4]. The onset and progression of this disease, is affected by several factors, such as
obesity, hypertension and diabetes mellitus [5–6]. The pathophysiological basis of the disease and its complication include inflammation and oxidative stress. These pathophysiological features are known to consistently occur in humans and animals [7–8]. They are also major mediators of the disease, exerting similar effects in a chronic renal failure (CRF) model in rats [9–11]. Patients and laboratory animals with CKD have high plasma concentrations of inflammatory mediators (such as C-reactive protein, tumor necrosis factor and other cytokines) and several markers of oxidative stress [12–13].

Chrysin (5, 7-dihydroxyflavone) is an important natural plant flavonoid (Fig 1) with diverse pharmacological activities that include antioxidant [14], antiinflammatory [15], antiapoptotic [16], anti-atherogenic [17] and anti-cancer properties [18]. In rats, chrysin has also recently been shown to ameliorate cisplatin and doxorubicin nephrotoxicity [19] and methotrexate and carbon tetrachloride hepatotoxicity [20–21].

In the present work, and in continuation of our research program aiming at identifying novel agents for either the prevention or amelioration of adenine–induced CRD in a rat model [9,12,22–23], we have studied here the effects of treatment with this polyphenolic compound on rats with adenine–induced CRF, using several conventional and novel physiological, biochemical, immunological and histopathological methods, with a special focus on the possible effects of chrysin on the anti-inflammatory and antioxidant mechanisms in adenine – induced CKD.

Materials and Methods

Animals

Male Wistar rats (9–10 weeks old, initially weighting about 245 g) were obtained from the Animal Facility of Sultan Qaboos University (SQU), and housed in a room at a temperature of 22±2°C, relative humidity of about 60%, with a 12 h light–dark cycle (lights on at 6:00 am), with free access to standard pellet chow diet containing 0.85% phosphorus, 1.12% calcium, 0.35% magnesium, 25.3% crude protein and 2.5 IU/g vitamin D3 (Oman Flour Mills, Muscat, Oman) and tap water. Procedures involving animals and their care were conducted as described before [22] and an ethical approval from University Animal Research Ethics Committee was obtained (SQU/AEC/13/01).
Experimental Design

Following an acclimatization period of one week, rats (n = 48) were randomly divided into eight equal groups and treated for five consecutive weeks. The 1st group continued to receive the same diet without treatment until the end of the study (control group). The 2nd group was switched to a powder diet containing adenine (0.25% w/w in feed) for 35 days. The 3rd, 4th, and 5th groups were given normal food and chrysin daily by gavage at doses of 10, 50 and 250 mg/kg, respectively. The 6th, 7th and 8th groups were given adenine in the feed as in the 2nd group, plus chrysin at the above doses, respectively. The dose of adenine was chosen from our recent modified method for the induction of CKD [10], and the doses of chrysin were selected to bracket the doses reported in the literature [16].

The rats were weighed weekly during the experimental period. Rats were placed individually in metabolic cages for 24 h to collect urine. Thereafter, the rats were anesthetized with ketamine (75 mg/kg) and xylazine (5 mg/kg) both injected intraperitoneally, and blood (about 6 mL) was obtained from the anterior vena cava and placed into heparinized tubes. The blood and urine were spinned at 900 g at 4°C for 15 min. The plasma and the urine specimens were kept frozen at −80°C pending analysis within a month after the end of the experiment. The kidneys were removed, blotted on filter paper and weighed. A small piece of the right kidney was placed in formol-saline for subsequent histopathological examination. The rest of the kidneys were kept frozen at −80°C pending biochemical and molecular analysis and Western blot. The left kidney was homogenized in ice-cold Tris buffer (pH 7.4) to give a 10% w/v homogenate. The renal homogenates were centrifuged at 1500 g at 4°C for 15 min, and the supernatant obtained was used to measure several indices of the oxidant status.

Biochemical Methods

The biochemical renal function tests in plasma and urine were measured using an automated analyzer as described before [22–23], except for plasma concentration of indoxyl sulfate (IS), which was assayed using an HPLC method, as previously described [24], and renal antioxidant and neutrophil gelatinase-associated lipocalin (NGAL), N-acetyl-β-D-glucosaminidase (NAG), and sclerostin, which were measured using ELISA.

Histopathology

From the kidneys, 2 μm sections were cut and stained with hematoxylin and eosin (HE), periodic acid-Schiff stain (PAS) and Masson Trichome (MT) stain to assess inflammation, fibrosis, atrophy of basal membrane as well as dilatation as described earlier [9].

Western blot analysis for caspase-3 and its cleaved isoform

Activation of the caspase cascade is a feature of apoptosis that is associated with CKD [10]. Therefore, we measured in this work the proteolytic activity of caspase-3 in the rat renal tissues collected from the eight different groups. The method used was described previously [22].

Drugs and Chemicals

Adenine and chrysin were obtained from Sigma (St. Louis, MO, USA). All the ELISA enzymes and cytokines were obtained from Biovision (Mountain View, CA, USA), the except kits of sclerostin, NAG and NGAL, which were bought from CloudClone Corp. (Houston, TX, USA), Diazyme (General Atomics, San Diego, CA, USA) and BiopORTO diagnostics (Grusbakken, Gentofte, Denmark), respectively. Antioxidant kits were bought from Randox (Antrim, UK).
Statistics

Data were expressed as means ± SEM, and were analyzed with GraphPad Prism Version 4.01 for Windows software (Graphpad Software Inc., San Diego, USA). Comparisons between groups were performed by analysis of variance (ANOVA), followed by Newman-Keuls multiple-range tests. *P* values <0.05 are considered significant.

Results

Physiological data

The general appearance of the adenine-treated rats was subjectively judged to be improved by chrysin treatment, especially at the highest dose (250 mg/kg). The kidneys from the control and chrysin-treated rats appeared normal. However, the kidneys of adenine-treated rats were pale, and a few crystals similar to those described for adenine were seen, mainly in the cortex area. The appearance of the kidneys of rats treated with adenine plus the three doses of chrysin were improved compared with the kidneys of rats treated with adenine alone.

The basic physiological data of the eight groups of rats in the experiment are shown in Table 1. Adenine treatment significantly reduced the growth of rats, and increased the absolute and relative kidney weight, the water intake and urine output (*P* < 0.05), but did not significantly affect either the feed intake or feces produced. Treatment with the three doses of chrysin caused a marked increase in the feed intake and body weights of rats, but did not affect the water intake of rats, nor their urine output. However, simultaneous feeding of rats with adenine and chrysin mitigated the effects of adenine treatment, which were statistically different for the water and urine output when the highest dose of chrysin was used.

| Group                          | Body weight change (%) | Relative kidney weight (%) | Water intake (mL) | Urine output (mL) |
|-------------------------------|------------------------|---------------------------|-------------------|------------------|
| Control                       | 28.5±2.3               | 0.7±0.02                  | 21.8±2.3          | 9.6±1.2          |
| Adenine                       | -5.1±1.9a              | 1.8±0.06a                 | 55.2±0.96a        | 47.2±1.3a        |
| Chrysin (10mg/Kg)             | 36.2±12.3b             | 0.6±0.01b                 | 20.2±2.3b         | 8.5±0.1b         |
| Chrysin (50mg/Kg)             | 38.6±10.3b             | 0.6±0.02b                 | 22.0±1.8b         | 10.6±0.5b        |
| Chrysin (250mg/Kg)            | 10.1±0.02b             | 0.5±0.01b                 | 15.2±1.5b         | 7.4±0.6b         |
| Chrysin (10mg/Kg)+Adenine     | 4.5±2.2cd              | 1.7±0.1acde               | 48.5±3.5acde      | 39.2±4.9acde     |
| Chrysin (50mg/Kg)+Adenine     | 5.6±1.7cd              | 1.7±0.1adde               | 45.0±4.1adde      | 38.2±2.6adde     |
| Chrysin (250mg/Kg)+Adenine    | 1.4±0.1cde             | 1.3±0.5                   | 35.6±5.5ce        | 26.3±3.3cdefg    |

Values in the tables are mean ± SEM (*n* = 6).

Chronic kidney disease (CKD) was induced by the inclusion of adenine in the feed at a concentration of 0.25% w/w for 35 days, and chrysin (10, 50, and 250mg/kg) was given orally by gavage either alone or concomitantly with adenine. On the last day of the treatment, the rats were placed in metabolic cages to collect urine.

Values with superscripts are statistically different *p* value

- *a* vs control
- *b* vs. Adenine
- *c* vs. Chrysin (10 mg/kg)
- *d* vs. Chrysin (50 mg/kg)
- *e* vs. Chrysin (250 mg/kg)
- *f* vs. Chrysin (10 mg/kg) + Adenine
- *g* vs. Chrysin (50 mg/kg) + Adenine.

![Image](https://example.com/image.png)

*doi:10.1371/journal.pone.0125285.t001*
Biochemical measurements

As shown in Fig 2, adenine treatment significantly increased creatinine and urea concentrations in plasma, and decreased creatinine clearance ($P < 0.05$). Adenine also increased the activities of urinary NAG and plasma NGAL. Treatment with the three doses of chrysin alone did not significantly affect any of the above indices, which were not significantly different from those of the controls ($P > 0.1$). Co-administration of chrysin at the three graded doses (10, 50 and 250 mg/kg) with adenine caused a significant and dose-dependent amelioration of all indices measured, except IS, which was insignificantly mitigated when compared with that in rats treated with adenine alone.

The effect of chrysin treatment on antioxidant indices in kidney homogenates from control rats and rats with adenine-induced CKD is shown in Fig 3. Adenine treatment significantly depressed SOD and catalase activities, GSH concentrations, and total antioxidant capacity. Treatment with chrysin alone at the three graded doses significantly enhanced these indices in a dose-dependent manner. Concomitant treatment of rats with adenine and the three doses of chrysin dose-dependently abated the adenine-induced oxidative stress ($P < 0.05$).

Table 2 shows the effect of the three doses of chrysin (with and without adenine co-treatment) on the activities of some enzymes in plasma. Adenine treatment caused significant and marked increases (about 2–4 fold) in the enzymes measured (ALT, AST, CK, GGT and LDH). The three doses of chrysin alone exerted no significant effect on any of the enzymatic activities. In the co-treated groups, the three doses of chrysin were effective in significantly ameliorating the action of adenine on the measured enzymes.

Adenine treatment caused a significant increase in the concentrations of indoxyl sulfate (IS) and cystatin C in plasma (Fig 4). Chrysin alone did not significantly affect either the IS or cystatin C concentrations. However, when adenine was given together with chrysin, there was a dose-dependent diminution in its concentration, which was statistically significant at all

![Fig 2. Effect of chrysin treatment on creatinine clearance, plasma concentrations of creatinine, urea and neutrophil gelatinase-associated lipocalin (NGAL), urinary albumin concentration and N-acetyl-β-D-glucosaminidase (NAG) activity in control rats and rats treated either singly or concomitantly with either adenine (ADE) or chrysin (C) at doses of 10, 50 or 250 mg/kg. Each column and vertical bar is a mean ± SEM (n = 6).](doi:10.1371/journal.pone.0125285.g002)
doses of chrysin (in case of IS, \( P < 0.001 \)), and at the highest dose of chrysin (in case of cystatin C, \( P < 0.001 \)).

As shown in Fig 5, adenine treatment significantly increased the plasma concentrations of endothelin – 1, adiponectin, TNF-\( \alpha \) and IL—\( \beta \), and decreased that of sclerostin (\( P < 0.001 \)).

Table 2. Effect of chrysin on the activities of some enzymes in plasma rats with adenine-induced chronic kidney disease.

| Enzyme                  | ALT (IU/L) | AST (IU/L) | CK (IU/L) | GGT (IU/L) | LDH (IU/L) |
|-------------------------|------------|------------|-----------|------------|------------|
| Control                 | 28.0±3.9   | 40.2±3.9   | 265.0±24.3| 1.5±0.3    | 189.0±14.2 |
| Adenine                 | 113.2±24.9 \(^a\) | 126.3±21.6 \(^a\) | 453.3±13.5 \(^d\) | 5.3±0.6 \(^a\) | 358.7±16.9 \(^d\) |
| Chrysin (10mg/Kg)       | 53.2±4.7 \(^b\) | 89.0±8.6   | 259.2±10.7 \(^b\) | 1.7±0.3 \(^b\) | 189.2±26.0 \(^b\) |
| Chrysin (50mg/Kg)       | 39.0±5.4 \(^b\) | 86.7±7.5   | 262.5±20.9 \(^b\) | 1.5±0.3 \(^b\) | 174.4±13.4 \(^b\) |
| Chrysin (250mg/Kg)      | 33.3±0.7 \(^b\) | 82.3±27.0  | 247.2±27.7 \(^b\) | 1.2±0.5 \(^b\) | 156.8±18.9 \(^b\) |
| Chrysin (10mg/Kg)+Adenine| 71.8±7.8   | 102.0±1.8  | 442.7±23.9 \(^abcd\) | 3.8±0.6 \(^abcd\) | 320.0±43.1 \(^abcd\) |
| Chrysin (50mg/Kg)+Adenine| 50.0±5.2   | 93.8±4.8   | 322.2±29.7 \(^d\)  | 3.2±0.7    | 275.3±17.9 \(^d\) |
| Chrysin (250mg/Kg)+Adenine| 41.3±1.3   | 66.3±3.2   | 310.2±25.7 \(^d\)  | 2.5±0.2    | 221.6±29.3 \(^d\) |

Values in the tables are mean ± SEM (n = 6).
Chronic kidney disease (CKD) was induced by the inclusion of adenine in the feed at a concentration of 0.25% w/w for 35 days, and chrysin (10, 50, and 250mg/kg) was given orally by gavage either alone or concomitantly with adenine. On the last day of the treatment, rats were killed for blood collection.

AST: aspartate aminotransferase, ALT: alanine aminotransferase, CK: creatinine kinase, GGT: gamma glutamyl transferase, LDH: lactate dehydrogenase.

Values with superscripts are statistically different \( p \) value

\(^a\) vs control
\(^b\) vs. Adenine
\(^c\) vs. Chrysin (10 mg/kg)
\(^d\) vs. Chrysin (50 mg/kg)
\(^e\) vs. Chrysin (250 mg/kg)
\(^f\) vs. Chrysin (10 mg/kg) + Adenine.
Treatment of rats with any of the three doses of chrysin alone did not significantly affect any of the above. Co-administration of chrysin and adenine produced a dose-dependent decrease in clusterin levels ($P < 0.05$) when compared with control rats and rats treated with chrysin alone. It did not significantly affect IL-1$\beta$ concentrations, but it markedly and significantly decreased the TNF-\(\alpha\) levels ($P < 0.001$) when compared with those in adenine–treated rats. The effect of chrysin treatment in the latter animals was less marked, and was only significant in the

Fig 4. Effect of chrysin treatment on plasma concentrations of indoxyl sulfate and cystatin in control rats and rats treated either singly or concomitantly with either adenine (ADE) or chrysin (C) at doses of 10, 50 or 250 mg/kg. Each column and vertical bar is a mean ± SEM (n = 6).

doi:10.1371/journal.pone.0125285.g004

Fig 5. Effect of chrysin treatment on plasma concentrations of the cytokines tumor necrosis factor alpha (TNF-\(\alpha\)), sclerostin adiponectin, interleukin–one beta (IL-1$\beta$) and endothelin in control rats and rats treated either singly or concomitantly with either adenine (ADE) or chrysin (C) at doses of 10, 50 or 250 mg/kg. Each column and vertical bar is a mean ± SEM (n = 6).

doi:10.1371/journal.pone.0125285.g005
case of endothelin – 1, and at the highest dose of chrysin. Adenine significantly decreased the concentration of sclerostin, and co-treatment with chrysin antagonized this action in a dose-dependent fashion, which was statistically significant at doses of 50 and 250 mg/kg.

Molecular analysis of apoptosis

The results of this part are shown in Fig 6 and the graph (showing the mean relative intensity of the un-cleaved and cleaved bands of the caspase-3 protein as measured optically using Image J) indicates that treatment with chrysin alone at the three different doses used did not affect apoptosis significantly ($P > 0.05$) in rat kidneys as shown by the low intensity of the cleaved bands, which were comparable with control kidneys. However, the concomitant treatment with adenine and chrysin did not exhibit any significant improvement in the degree of apoptosis induced by adenine, which was represented by the thick cleaved bands of caspase-3 (25 KDa) that was comparable with the cleaved band obtained by the single treatment with 0.25% of adenine (far right of the blot).

Histopathology

Histopathological examination of kidney sections from control rats showed no sign of damage. As shown in Table 3 and Fig 7, the kidneys of adenine-treated animals showed several signs of extensive damage, including inflammation, as well as fibrosis. Chrysin alone did not significantly alter the morphological appearance of the kidneys. In combination with adenine, the pathology was slightly ameliorated; the best was at the lowest concentration of chrysin.

Discussion

Nephroprotection using natural products (such as the flavonoid chrysin that we have investigated here) may be a safe, efficacious, and cost-effective option to protect kidneys against aggressive factors, and to obviate the progression of renal impairment to the stage of renal failure where either dialysis or kidney transplantation are the only available options. Both options may be costly or even unavailable in many parts of the developing countries [25–28].
This is, as far as we are aware, the first study on the effect of chrysin on an adenine-induced model for CRF. While this work was being written up, a paper on the beneficial effect of chrysin in experimental diabetic nephropathy was published [29], and was broadly in line with a few of the results we obtained here, but different with some.

In this work, rats were treated with adenine to induce CKD, and concomitantly give chrysin as a preventive agent. In a subsequent experiment we will give chrysin after the end of the adenine treatment to test its possible therapeutic action on CKD.

Adenine induced various pathological signs of CKD in the rats, as shown in previously published work [12,22]. In this work, we measured, for the first time in rats with adenine–induced CKD, the cytokine sclerostin, which is a newly characterized blood marker of CKD in humans [30–31] and rats with 5/6-nephrectomy–induced CKD [32].

The modest beneficial effects seen in the present work are somewhat different from the results of Ahad et al [29], who reported that chrysin (at a single oral dose of 40 mg/kg for 16 consecutive weeks) completely prevented the development of diabetic nephropathy in rats. The possible reasons for the discrepancy between our results and those of Ahad et al. [29], are that diabetes nephropathy is not as damaging to the kidneys as adenine, and its nephropathy may be brought about by different mechanisms [33]. In addition, our treatment with the three graded doses was for five weeks. However, and in agreement with Ahad et al. [29], our results also indicated that adenine treatment has induced a highly significant increase in the concentrations of some inflammatory cytokines (particularly TNF–α), and this effect has been significantly and markedly suppressed by chrysin treatment at the three doses given. TNF–α is an important pro-inflammatory cytokine with prominent effects in many conditions [30], which include adenine–induced CKD [9]. The inhibitory effect of chrysin on TNF–α suggests that this phytochemical has exerted its ameliorative effect on adenine–induced CKD, at least partly, by an antiinflammatory action. However, chrysin in our work did not show a significant

| Group                        | Inflammation  | Fibrosis     | Atrophy     | Dilatation |
|------------------------------|---------------|--------------|-------------|------------|
| Control                      | 0.08±0.02     | 0            | 0           | 0          |
| Adenine 2.52±0.25a           | 3.03±0.18a    | 2.73±0.40a   | 0.20±0.05   |
| Chrysin (10mg/Kg)            | 0.24±0.05     | 0.17±0.03    | 0           |
| Chrysin (50mg/Kg)            | 0.24±0.06     | 0.23±0.07    | 0           |
| Chrysin (250mg/Kg)           | 0.18±0.06     | 0.30±0.10    | 0           |
| Chrysin (10mg/Kg)+Adenine    | 2.1±0.16abc   | 1.7±0.21abc  | 0.34±0.05abc|
| Chrysin (50mg/Kg)+Adenine    | 2.68±0.20abdf | 2.35±0.12abdf| 0.59±0.05abdf|
| Chrysin (250mg/Kg)+Adenine   | 2.66±0.10abef | 2.67±0.10abef| 0.54±0.07abef|

Values with superscripts are statistically different p value

* vs control

b vs. Adenine
c vs. Chrysin (10 mg/kg)
d vs. Chrysin (50 mg/kg)
e vs. Chrysin (250 mg/kg)
f vs. Chrysin (10 mg/kg) + Adenine

Values in the tables are mean ± SEM (n = 6)

Chronic kidney disease was induced by inclusion of adenine in the feed at a concentration of 0.25 0% w/w for 35 days, and chrysin (10, 50 & 250 mg/kg) was given orally by gavage either alone or concomitantly with adenine. Histopathology was evaluated from kidney slices stained with hematoxylin, Masson trichrome and periodic schiff acid.

doi:10.1371/journal.pone.0125285.t003
effect on the adenine-induced increase in the plasma concentration of the proinflammatory cytokine. The reason for this inconsistency with the results compared to the other proinflammatory cytokine TNF-α is not known. Recently the antiinflammatory action of chrysin has been confirmed in a mouse model of focal cerebral ischemia/reperfusion injury by inhibiting the NF-κB signaling pathway, which is a regulator of the expression of iNOS and COX-2. [34]. In this work, we measured for the first time in rats with adenine-induced CKD the cytokine sclerostin, which is a newly-characterized blood marker of CKD in humans [30–31] and rats with 5/6-nephrectomy-induced CKD [32]. Our results confirm the usefulness of sclerostin as a biomarker for CKD. Although the full significance of its measurement in either plasma or serum is not known with certainty, it has been found to be associated with several biological and clinical data in hemodialysis patients [31,35]. Here, we found that adenine has depressed the level of sclerostin, and that co-administration of chrysin in adenine-treated rats also antagonized the adenine-induced suppression of sclerostin. It has been shown in a single report that the sclerostin plasma level is significantly depressed in rats with CKD induced surgically by nephrectomy [36], an action related to its role as a Wnt/β-catenin pathway inhibitor.

As has been found in our previous papers adenine induced a highly significant increase in the plasma concentration of the tryptophan–derived uremic toxin IS [9–10]. Chrysin significantly and dose-dependently reversed this action (Fig 4). The mechanism by which this reduction has occurred has not been investigated here, but it has been shown previously that the levels of IS are lowered by preventing the bacterial generation of indole or by absorbing the latter within the intestine [37–38].
The present results also suggest that chrysin had no adverse effect on the hepatic and renal functions of treated rats, nor on either their water and feed intake, or fecal and urinary output. The relative safety of this flavonoid suggests that, pending further pharmacological and toxicological investigations, it could be a candidate for further studies as a nephroprotectant agent in humans. It should be mentioned, however, that a recent in vitro study reported that, at a relatively high concentration, chrysin showed an inhibitory action on 6-phosphogluconate dehydrogenase activity in human erythrocytes [39]. The significance of this is not known, and warrants further studies in vivo.

In this work, chrysin was not able to ameliorate significantly the morphological damage induced by adenine in the kidney as well as the physiological and biochemical endpoints. Using molecular quantification of apoptosis, chrysin did not cause any significant increase in caspase-3 levels indicating, in part, its lack of toxicity to the kidneys, and this was also confirmed by light histopathology examination. On the other hand, it did not show any significant improvement in kidneys of rats treated with adenine. This result contradicts the observations of Ahad et al. [29], who noticed a marked improvement in histopathological changes in kidneys of diabetic rats. It has to be stated that from the appearance of the kidneys in Ahad’s study the damage inflicted to them by the diabetes was not as severe as the damage we observed in the adenine animals. So the relative amelioration might be similar. Further, we concentrated our examination on the tubular system, which is mainly affected by adenine, while Ahad et al. [29] showed mostly changes in glomeruli. An explanation for better renal function endpoints despite only slightly better histological appearance might be that histological lesions appear before the appearance of either proteinuria or renal functional deterioration, as extensively studied in renal transplant patients [40]. Thus, the kidney is able to compensate for its histological damage, and with chrysin, maybe this compensation was improved.

In conclusion, this work has shown that the three graded doses of chrysin were modestly effective in mitigating some of the actions of adenine-induced CKD in rats. Further studies are warranted to confirm the usefulness and safety of chrysin as either an adjunct agent for the therapy or prevention of this condition. Before extrapolating these results to humans with CKD, more research is needed to verify the safety of increasing doses of chrysin in volunteers. A single report studied the disposition and metabolism of chrysin in seven healthy volunteers, each receiving a single dose of about 5 mg/kg [41]. It was found that chrysin undergoes extensive metabolism, and has low bioavailability.

The molecular mechanism(s) of antiinflammatory and antioxidant actions of chrysin in adenine-induced CKD are not known with certainty and has not been studied here. However, several possible mechanisms have been suggested. These include modulating the peroxisome proliferator activated receptor gamma and decreasing the expressions of the pro-inflammatory nuclear factor kappa-B (NF-κB) signaling pathway [42–43].

Acknowledgments
We would like to thanks P. Manog and the staff of SQU Animal House.

Author Contributions
Conceived and designed the experiments: BHA. Performed the experiments: BHA SA MAZ MIW JY AN NS. Analyzed the data: BHA. Contributed reagents/materials/analysis tools: BHA MAZ. Wrote the paper: BHA MAZ.
References
1. Hanson L, Haynes LK, Turiano L. Chronic kidney disease in Central America: the big picture. Am J Public Health. 2014; 104: e9. doi: 10.2105/AJPH.2014.302295 PMID: 25320888
2. Sengul S, Erdem Y, Batuman V, Erturk S. Hypertension and chronic kidney disease in Turkey. Kidney Int Suppl. 2011; 3: 309–311.
3. Yamagata K, Yagisawa T, Nakai S, Nakayama M, Imai E, Hattori M, et al. Prevalence and incidence of chronic kidney disease stage G5 in Japan. Clin Exp Nephrol. 2015; 19: 54–64. doi: 10.1007/s10157-014-0978-x PMID: 24821288
4. Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int. 2011; 80: 1258–1270. doi:10.1038/ki.2011.368 PMID: 21993585
5. Hall ME, do Carmo JM, da Silva AA, Juncos LA, Wang Z, Hall JE. Obesity, hypertension, and chronic kidney disease. Int J Nephrol Renovasc Dis. 2014; 7: 75–88. doi:10.2147/IJNRD.S39739 PMID: 24600241
6. Kazancioglu R. Risk factors for chronic kidney disease: an update. Kidney Int Suppl (2011). 2013; 3: 368–371. PMID: 25019021
7. Jablonski KL, Decker E, Perrenoud L, Kendrick J, Chonchol M, Seals DR, et al. Assessment of vascular function in patients with chronic kidney disease. J Vis Exp. 2014; 16.
8. Yilmaz MI, Siriopol D, Saglam M, Kurt YG, Unal HU, Eyileten T, et al. Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kidney Int. 2014; 86: 1213–1220. doi:10.1038/ki.2014.227 PMID: 24988065
9. Ali BH, Al-Husseni I, Beegam S, Al-Shukaili A, Nemmar A, Schierling S, et al. Effect of gum arabic on oxidative stress and inflammation in adenine-induced chronic renal failure in rats. PLoS One. 2011; 8: e55242. doi:10.1371/journal.pone.0055242 PMID: 23383316
10. Ali BH, Al-Salam S, Al Za’abi M, Waly MI, Ramkumar A, Beegam S, et al. New model for adenine-induced chronic renal failure in mice, and the effect of gum acacia treatment thereon: comparison with rats. J Pharmacol Toxicol Methods. 2013; 68: 384–393. doi:10.1016/j.vascn.2013.05.001 PMID: 23669035
11. Yamaguchi S, Inada C, Tamura M, Sato N, Yamada M, Itaba S, et al. Beraprost sodium improves survival rates in anti-glomerular basement membrane glomerulonephritis and 5/6 nephrectomized chronic kidney disease rats. Eur J Pharmacol. 2013; 714: 325–331. doi:10.1016/j.ejphar.2013.07.032 PMID: 23911885
12. Ali BH, Al-Salam S, Al Husseni I, Kayed RR, Al-Masroori N, Al-Harthi T, et al. Effects of gum Arabic in rats with adenine-induced chronic renal failure. Exp Biol Med (Maywood). 2010; 235: 373–382. doi: 10.1258/ebm.2009.009214 PMID: 20404056
13. Aminquist T, Jacobson SH, Mobarrez F, Näsman P, Hjemdahl P. Lipid-lowering treatment and inflammatory mediators in diabetes and chronic kidney disease. Eur J Clin Invest. 2014; 44: 276–284. doi: 10.1111/eci.12230 PMID: 24720535
14. Anand KV, Mohamed Jaabir MS, Thomas PA, Geraldine P. Protective role of chrysin against oxidative stress in d-galactose-induced aging in an experimental rat model. Geriatr Gerontol Int. 2012; 12: 741–750. doi:10.1111/j.1447-0594.2012.00843.x PMID: 22469068
15. Feng X, Qin H, Shi Q, Zhang Y, Zhou F, Wu H, et al. Chrysin attenuates inflammation by regulating M1/M2 status via activating PPARγ. Biochem Pharmacol. 2014; 89: 503–514. doi:10.1016/j.bcp.2014.03.016 PMID: 24704474
16. Jiang Y, Gong FL, Zhao GB, Li J. Chrysin suppressed inflammatory responses and the inducible nitric oxide synthase pathway after spinal cord injury in rats. Int J Mol Sci. 2014; 15: 12270–12278. doi:10.3390/ijms150712270 PMID: 25014398
17. Anandhi R, Thomas PA, Geraldine P. Evaluation of the anti-atherogenic potential of chrysin in Wistar rats. Mol Cell Biochem. 2014; 385: 103–113. doi:10.1007/s11010-013-1819-z PMID: 24065391
18. Rehman MU, Tahir M, Khan AQ, Khan R, Lateef A, Oday-O-Hamiza, et al. Chrysin suppresses renal carcinogenesis via amelioration of hyperproliferation, oxidative stress and inflammation: plausible role of NF-κB. Toxicol Lett. 2013; 216: 146–158. doi:10.1016/j.toxlet.2012.11.013 PMID: 23194824
19. Rashid S, Ali N, Nafees S, Ahmad ST, Arijumand W, Hasan SK, et al. Alleviation of doxorubicin-induced nephrotoxicity and hepatotoxicity by chrysin in Wistar rats. Toxicol Mech Methods. 2013; 23: 337–345. doi:10.3109/15376516.2012.759306 PMID: 23256457
20. Ali N, Rashid S, Nafees S, Hasan SK, Sultana S. Beneficial effects of Chrysin against methotrexate-induced hepatotoxicity via attenuation of oxidative stress and apoptosis. Mol Cell Biochem. 2014; 385: 215–223. doi:10.1007/s11010-013-1930-4 PMID: 24154663
21. Anand KV, Anandhi R, Pakkiyaraj M, Geraldine P. Protective effect of chrysin on carbon tetrachloride (CCl4)-induced tissue injury in male Wistar rats. Toxicol Ind Health. 2011; 27: 923–933. doi: 10.1177/0748237111399324 PMID: 21511893

22. Ali BH, Al-Salam S, Al-Za’abi M, Al Balushi KA, Ramkumar A, Waly MI, et al. Does swimming exercise affect experimental chronic kidney disease in rats treated with gum acacia? PLoS One. 2014; 9: e102528. doi: 10.1371/journal.pone.0102528 PMID: 25048380

23. Ali BH, Al-Za’abi M, Ramkumar A, Al-Lawati I, Waly MI, Beegam S, et al. The effect of activated charcoal on adenine-induced chronic renal failure in rats. Food Chem Toxicol. 2014; 65: 321–328. doi: 10.1016/j.fct.2013.12.038 PMID: 24412558

24. Al-Za’abi M, Ali B H, Al Toubi M. HPLC-fluorescence method for measurement of the uremic toxin indoxyl sulfate in plasma. J Chromatogr Sci. 2013; 51: 40–43. doi: 10.1093/chromsci/bms103 PMID: 22718744

25. Ahmad OZ, Jahan N, Ahmad G, Tajuddin. An appraisal of nephroprotection and the scope of natural products in combating renal disorders. J Nephrol Ther. 2014; 4: 170.

26. Huang Y, Lei Y, Zheng Z, Wang X, Hu M, Liu R, et al. Rosiglitazone alleviates injury in rats with adenine-induced chronic kidney disease. Mol Med Rep. 2013; 8: 1831–5. doi: 10.3892/mmr.2013.1715 PMID: 24126724

27. Tu Y, Sun W, Wan YG, Gao K, Liu H, Yu BY, et al. Dahuang Fuzi Decoction ameliorates tubular epithelial apoptosis and renal damage via inhibiting TGF-β1-JNK signaling pathway activation in vivo. J Ethnopharmacol. 2014; 156: 115–24. doi: 10.1016/j.jep.2014.08.035 PMID: 25193680

28. Diwan V, Gobe G, Brown L. Gilbenclamide improves kidney and heart structure and function in the adenine-diet model of chronic kidney disease. Pharmacol Res. 2014; 79: 104–10. doi: 10.1016/j.phrs.2013.11.007 PMID: 24291534

29. Ahad A, Ganai AA, Mujeeb M, Siddiqui WA. Chrysin, an anti-inflammatory molecule, abrogates renal dysfunction in type 2 diabetic rats. Toxicol Appl Pharmacol. 2014; 279: 1–7. doi: 10.1016/j.taap.2014.05.007 PMID: 24848621

30. Holmes D. Biomarkers: Sclerostin levels linked to CKD outcomes. Nat Rev Endocrinol. 2014; 10: 577. doi: 10.1038/nrendo.2014.145 PMID: 25112232

31. Desjardins L, Liabeuf S, Oliveira RB, Louvet L, Kamel S, Lemke HD, et al. On behalf of the European Uremic Toxin (EUTox) Work Group. Uremic toxicity and sclerostin in chronic kidney disease patients. J Nephrol Ther. 2014; 10: 463–70. doi: 10.1016/j.jneph.2014.04.002 PMID: 25070604

32. Martín-Pardillos A, Sosa C, Millán Á, Sorribas V. Effect of water fluoridation on the development of medial vascular calcification in uremic rats. Toxicology. 2014; 318: 40–50. doi: 10.1016/j.tox.2014.01.012 PMID: 24561004

33. García-García PM, Getino-Melián MA, Domínguez-Pimentel V, Navarro-González JF. Inflammation in diabetic kidney disease. World J Diabetes. 2014; 5: 431–443. doi: 10.4239/wjd.v5.i4.431 PMID: 25126391

34. Yao Y, Chen L, Xiao J, Wang C, Jiang W, Zhang R, et al. Chrysin protects against focal cerebral ischemia / reperfusion injury in mice through attenuation of oxidative stress and inflammation. Int J Mol Sci. 2014; 15: 20926–20932. doi: 10.3390/ijms151120913 PMID: 25402649

35. Delanaye P, Krzesinski JM, Warling X, Moonen M, Smelten N, Médart L, et al. Clinical and biological determinants of sclerostin plasma concentration in hemodialysis patients. Nephron Clin Pract. 2014; 128: 127–34. doi: 10.1159/000366449 PMID: 25377055

36. Ferreira JC, Ferrari GO, Neves KR, Cavallari RT, Dominguez WV, Dos Reis LM, et al. Effects of dietary phosphate on adynamic bone disease in rats with chronic kidney disease—role of sclerostin? PLoS One. 2013; 8:e79721. doi: 10.1371/journal.pone.0079721 PMID: 24236156

37. Owada S, Goto S, Bannai K, Hayashi H, Nishijima F, Niwa T. Indoxyl sulfate reduces superoxide scavenging activity in the kidneys of normal and uremic rats. Am J Nephrol. 2008; 28: 446–54. doi: 10.1002/jbt.21592 PMID: 18160814

38. Taki K, Nakamura S, Miglinas M, Enomoto A, Niwa T. Accumulation of indoxyl sulfate in OAT1/3-positive tubular cells in kidneys of patients with chronic renal failure. J Ren Nutr. 2006; 16:199–203. PMID: 16825019

39. Adem S, Comakli V, Kuzu M, Demirdag R. Investigation of the effects of some phenolic compounds on the activities of glucose-6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase from human erythrocytes. J Biochem Mol Toxicol. 2014; 28: 510–4. doi: 10.1002/jbt.21592 PMID: 25130191

40. Serón D, Burgos D, Alonso A. Histology and proteinuria after renal transplantation. Transplant Rev (Orlando). 2012; 26: 20–26. doi: 10.1016/j.trre.2011.07.009 PMID: 22137728

41. Walle T, Otake Y, Brubaker JA, Walle UK, Halushka PV. Disposition and metabolism of the flavonoid chrysin in normal volunteers. Br J Clin Pharmacol. 2001; 51: 143–6. PMID: 11259985
42. Feng X, Qin H1, Shi Q, Zhang Y, Zhou F, Wu H, et al. Chrysin attenuates inflammation by regulating M1/M2 status via activating PPARγ. Biochem Pharmacol. 2014; 89: 503–14. doi:10.1016/j.bcp.2014.03.016 PMID: 24704474

43. Romier B, Van De Walle J, During A, Larondelle Y, Schneider YJ. Modulation of signalling nuclear factor-kappaB activation pathway by polyphenols in human intestinal Caco-2 cells. Br J Nutr. 2008; 100: 542–51. doi:10.1017/S0007114508966666 PMID: 18377686